Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
37
BRKR Quote, Financials, Valuation and Earnings
Last price:
$41.74
Seasonality move
:
0%
Day range:
$40.99 - $42.24
52-week range:
$34.10 - $72.94
Dividend yield:
0.48%
P/E ratio:
79.93x
P/S ratio:
1.82x
P/B ratio:
3.47x
Volume:
2M
Avg. volume:
2.5M
1-year change:
-37.3%
Market cap:
$6.3B
Revenue:
$3.4B
EPS (TTM):
$0.52
Analysts' Opinion
-
Consensus RatingBruker has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $54.11, Bruker has an estimated upside of 30.26% from its current price of $41.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $40.00 representing 3.71% downside risk from its current price of $41.54.
Fair Value
-
According to the consensus of 12 analysts, Bruker has 30.26% upside to fair value with a price target of $54.11 per share.
BRKR vs. S&P 500
-
Over the past 5 trading days, Bruker has underperformed the S&P 500 by -1.44% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bruker does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bruker has grown year-over-year revenues for 18 quarters straight. In the most recent quarter Bruker reported revenues of $801.4M.
Earnings Growth
-
Bruker earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Bruker reported earnings per share of $0.11.
Enterprise value:
8.3B
EV / Invested capital:
--
Price / LTM sales:
1.82x
EV / EBIT:
38.46x
EV / Revenue:
2.41x
PEG ratio (5yr expected):
2.41x
EV / Free cash flow:
47.66x
Price / Operating cash flow:
35.93x
Enterprise value / EBITDA:
20.01x
Gross Profit (TTM):
$1.7B
Return On Assets:
1.41%
Net Income Margin (TTM):
2.31%
Return On Equity:
4.53%
Return On Invested Capital:
2.11%
Operating Margin:
8.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.6B | $3B | $3.4B | $721.7M | $801.4M | |
| Gross Profit | $1.4B | $1.5B | $1.7B | $352.8M | $391.2M | |
| Operating Income | $486.9M | $436.8M | $371.5M | $74.9M | $65.7M | |
| EBITDA | $534.8M | $650.9M | $415.9M | $111.3M | $88.6M | |
| Diluted EPS | $2.10 | $2.75 | $0.52 | $0.35 | $0.11 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.9B | $2.3B | $2.1B | $2.1B | $2.1B | |
| Total Assets | $3B | $3.6B | $3.8B | $4.5B | $5.9B | |
| Current Liabilities | $943.5M | $880.5M | $1B | $1.2B | $1.3B | |
| Total Liabilities | $2.1B | $2.5B | $2.6B | $3.1B | $4.1B | |
| Total Equity | $981.7M | $1B | $1.2B | $1.5B | $1.9B | |
| Total Debt | $824.2M | $1.2B | $1.2B | $1.4B | $2.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $284.1M | $284.4M | $294.5M | $21.8M | $65M | |
| Cash From Investing | -$258M | -$522M | -$1.5B | -$304.2M | -$26.1M | |
| Cash From Financing | -$228.6M | -$11M | $1B | $151.7M | -$51.2M | |
| Free Cash Flow | $148.9M | $181.1M | $174.6M | $400K | $39M | |
BRKR
Sector
Market Cap
$6.3B
$34.4M
Price % of 52-Week High
56.95%
48.88%
Dividend Yield
0.48%
0%
Shareholder Yield
-8.32%
-1.01%
1-Year Price Total Return
-37.3%
-37.36%
Beta (5-Year)
1.181
0.614
Dividend yield:
0.48%
Annualized payout:
$0.20
Payout ratio:
38.44%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$42.48
200-day SMA
Sell
Level
$50.09
Bollinger Bands (100)
Buy
Level
37.18 - 45.2
Chaikin Money Flow
Buy
Level
67.9M
20-day SMA
Buy
Level
$41.26
Relative Strength Index (RSI14)
Buy
Level
52.45
ADX Line
Buy
Level
23.45
Williams %R
Neutral
Level
-70.7158
50-day SMA
Buy
Level
$39.43
MACD (12, 26)
Buy
Level
0.96
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
58.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8009)
Sell
CA Score
(Annual)
Level (-0.8277)
Buy
Beneish M-Score
(Annual)
Level (-2.2686)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.149)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Stock Forecast FAQ
In the current month, BRKR has received 5 Buy ratings 7 Hold ratings, and 0 Sell ratings. The BRKR average analyst price target in the past 3 months is $54.11.
-
Where Will Bruker Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bruker share price will rise to $54.11 per share over the next 12 months.
-
What Do Analysts Say About Bruker?
Analysts are divided on their view about Bruker share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bruker is a Sell and believe this share price will drop from its current level to $40.00.
-
What Is Bruker's Price Target?
The price target for Bruker over the next 1-year time period is forecast to be $54.11 according to 12 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is BRKR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bruker is a Hold. 7 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BRKR?
You can purchase shares of Bruker via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bruker shares.
-
What Is The Bruker Share Price Today?
Bruker was last trading at $41.74 per share. This represents the most recent stock quote for Bruker. Yesterday, Bruker closed at $41.54 per share.
-
How To Buy Bruker Stock Online?
In order to purchase Bruker stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
